AzTrials
AzTrials

Poor Ovarian ResponseNCT04013984

Acupuncture for Treatment of Patients With Poor Ovarian Response

A study testing Accupuncture in people with Poor Ovarian Response and Accupuncture, run by Royan Institute at 1 site in Iran.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This prospective randomized controlled trial is designed to investigate the effect of acupuncture on IVF/ICSI outcome in women with poor ovarian response. The study population consisted of all infertile women with a previous poor ovarian response who will undergo IVF/ICSI in Reproductive Biomedicine Research Center… Read more about this study

Who is it for?
Ages 20 to 35 years, women onlyHealthy volunteers can take part
Conditions the study is for
Poor Ovarian Response, Accupuncture
What is being tested?
Accupuncture
Could I receive a placebo?
No, everyone receives an active treatment
How many people
43 participants
Where
1 siteIran
Study dates
1 Oct 2018to 20 Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • 1- Diagnosis of Poor ovarian response (POR), according to POSSEIDON group criteria (Group 3) Young patients (<35 years) with poor ovarian reserve prestimulation parameters (AFC <5, AMH<1.2 ng/mL).

Who cannot join

  • Premature ovarian failure diagnosis.
  • Endometriosis grade III or IV.
  • Any contraindications to ovarian stimulation treatment.
  • Uterine infertility factor.
  • Previous history of ovarian surgery.

Trial locations and contacts

1 site in 1 country.

Iran1 site
  • Royan Institute

    Tehran, 16635-148

Other trials in Iran

About this study

Official title: The Effect of Acupuncture on in Vitro Fertilization/ Intracytoplasmic Sperm Injection Embryo Transfer (IVF/ICSI-ET) Outcomes in Patients With Poor Ovarian Response Diagnosis: A Randomized Controlled Trial

This prospective randomized controlled trial is designed to investigate the effect of acupuncture on IVF/ICSI outcome in women with poor ovarian response. The study population consisted of all infertile women with a previous poor ovarian response who will undergo IVF/ICSI in Reproductive Biomedicine Research Center, Royan institute, Tehran Iran. To minimize the effect of ovarian stimulation protocol, a stratified randomization method according to ovarian stimulation protocols (GnRH agonist stopped and GnRH antagonist) is used.

Read the detailed description

Poor ovarian response (POR) is a challenging issue in assisted reproduction treatment. Different controlled ovarian hyperstimulation protocols and strategies have been used in this group of women to improve reproductive outcome, but the success rate still remains low. The aim of this study was to determine the effect of acupuncture during ovulation induction on the results of IVF / ICSI cycles in patients with POR diagnosis. The study was approved by the institutional review board. Written, informed consent will be obtained from each participant. Infertile women with a diagnosis of POR, who undergoing the IVF / ICSI cycle are assigned to four groups by stratified randomization method according to ovarian stimulation protocol. Before the starting the treatment cycle, patients will be randomized with sealed randomization envelopes. The random allocation is concealed from the physician performing the IVF/ICSI treatment cycle. All patients will receive acupuncture by the same physician (Dr.Salimi). In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons. There is no intervention in the control groups (B).

Controlled ovarian stimulation for patients in both groups will be performed according the long stopped protocol. GnRH agonist (Buserelin, 0.5 mg), beginning on day 18 of the previous cycle will be used for down regulation and then will be stopped on the starting ovarian stimulation. Ovarian stimulation will be done with recombinant FSH and hMG (225 IU recombinant FSH (Gonal-F®; Serono Laboratories Ltd., Geneva, Switzerland) and 75 IU hMG (Menopur®; Ferring). The doses of gonadotropins were adjusted as ovarian response in the ultrasound monitoring. Ovulation was triggered with hCG (10,000 IU) when at least three follicles have a diameter of 18 mm with an adequate serum E2 concentration.

In both group, transvaginal oocyte retrieval will be performed under ultrasound guidance 32-34 hours after hCG administration. Intracytoplasmic sperm injection will be performed for all metaphase II oocytes. Embryo transfer will be done under ultrasound guidance on day 3 for all patients.

Primary consequences in this study are the total number of retrieved and MII oocytes and quality of the obtained embryos. Secondary outcomes are implantation and clinical pregnancy rates that confirmed by vaginal ultrasound (pregnancy sac and embryonic heart activity). The IVF/ICSI outcomes are compared in four groups. Data collection will be performed by using questionnaire to be filled as per the available records and laboratory results. Data analysis will be done through descriptive and perceptive statistical methods by using SPSS software version 20 for windows.

Being tested
Accupuncture

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AccupunctureOther

    In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons

Study groups in NCT04013984
Study groupRoleWhat they receive
AccupunctureExperimentalAcupuncture twice a week during the preceding cycle and the ovarian stimulation by "GnRH agonist stopped protocol".
Receives: Other: Accupuncture
Non-accupunctureNo interventionOvarian stimulation by" GnRH agonist stopped protocol" without intervention.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total number of retrieved oocytes

    At the point of ovum pick-up, we can count total number of retrieved oocytes. Therefore, in one hour after ovum pick-up, outcome measurement will be possible.

    Measured: Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)

  2. Oocyte maturity

    At the point of ovum pick-up, we can count how many mature or immature oocytes were retrieved. Therefore, in one hour after ovum pick-up, outcome measurement will be possible.

    Measured: Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)

  3. Quality of obtained embryos

    Embryo grade assessed under invert microscope 3 days after intracytoplasmic sperm injection procedure [ Time Frame: 3 days after intracytoplasmic sperm injection procedure ] Embryo grade assessed under invert microscope 3 days after intracytoplasmic sperm injection procedure.The quality of embryos was graded from 1 to 3 under inverted microscope 3 days after intracytoplasmic sperm injection procedure. Embryos with even-sized blastomers and/or <5% fragments were classified as Grade 1 (good quality). Grade 2 embryos (moderate quality) had blastomeres with slightly-moderate size differences and/or 5-50% fragments. Grade 3 embryos (poor quality) had markedly different-sized blastomers and/or >50% fragments.

    Measured: 3 days after IVF/ICSI procedure

Secondary outcomes (2)
  1. Implantation rate

    The ratio of total number of observed gestational sacs to total number of transferred embryos.

    Measured: 4 weeks after embryo transfer

  2. Clinical pregnancy rate

    The observation of gestational sac with heart beat by using trans-vaginal ulterasound

    Measured: 4-6 weeks after embryo transfer

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2019
  2. Study start1 Oct 2018
  3. Primary completion20 Jan 2021
  4. Study completion20 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Parallel Assignment
Masking
None (open label)
Enrolment
43 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04013984
Sponsor's protocol ID
POR-accupuncure
Status last verified
Jun 2023
First submitted
8 Apr 2019
Last updated
15 Jun 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: We can share the results of study, after the publish the manuscript.

Questions about this trial

What is this clinical trial studying?

A study testing Accupuncture in people with Poor Ovarian Response and Accupuncture, run by Royan Institute at 1 site in Iran.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total number of retrieved oocytes (time frame: Day of oocyte pick-up, 34-36 hours after hCG administration (approximately Stimulation Day 10)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in